Publication | Open Access
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial
79
Citations
33
References
2023
Year
UrologyGenitourinary CancerMedicinePharmacologyProfound TrialPharmacotherapyCancer TreatmentProstatic DiseaseProstatecancer PatientsOncologyRadiation OncologyMolecular Oncology
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
| Year | Citations | |
|---|---|---|
Page 1
Page 1